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Background
Improving the functional avidity of effector T cells is
critical in overcoming inhibitory factors within the
tumor microenvironment and eliciting tumor regression.
Methods
We have found that Cish, a member of the Suppressor
of Cytokine Signaling (SOCS) family, is induced by TCR
stimulation in CD8+ T cells and inhibits their functional
avidity against tumor.
Results
Genetic deletion of Cish in CD8+ T cells enhances their
expansion, functional avidity and cytokine polyfunction-
ality, resulting in pronounced and durable regression of
established tumors. Although Cish is commonly thought
to block STAT5 activation, we found that the primary
molecular basis of Cish suppression is through inhibi-
tion of TCR signaling. Cish physically interacts with the
TCR intermediate PLCg1, targeting it for proteasomal
degradation following TCR stimulation. Furthermore we
extend these findings to patients PBL retrovirally trans-
duced with tumor-specific TCRs and shorthairpin
microRNAs targeting CISH.
Conclusions
These findings establish a novel targetable interaction
that regulates the functional avidity of tumor-specific
CD8+ T cells and can be manipulated to improve adop-
tive cancer immunotherapy.
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